Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Current Assets: 2014-2025

Historic Current Assets for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $738.7 million.

  • Viking Therapeutics' Current Assets fell 21.13% to $738.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $738.7 million, marking a year-over-year decrease of 21.13%. This contributed to the annual value of $907.2 million for FY2024, which is 147.05% up from last year.
  • Per Viking Therapeutics' latest filing, its Current Assets stood at $738.7 million for Q3 2025, which was down 10.68% from $827.0 million recorded in Q2 2025.
  • Viking Therapeutics' Current Assets' 5-year high stood at $966.3 million during Q1 2024, with a 5-year trough of $149.5 million in Q1 2023.
  • For the 3-year period, Viking Therapeutics' Current Assets averaged around $680.5 million, with its median value being $827.0 million (2025).
  • In the last 5 years, Viking Therapeutics' Current Assets dropped by 26.37% in 2022 and then soared by 546.52% in 2024.
  • Viking Therapeutics' Current Assets (Quarterly) stood at $210.5 million in 2021, then declined by 20.66% to $167.0 million in 2022, then skyrocketed by 119.84% to $367.2 million in 2023, then spiked by 147.05% to $907.2 million in 2024, then declined by 21.13% to $738.7 million in 2025.
  • Its Current Assets was $738.7 million in Q3 2025, compared to $827.0 million in Q2 2025 and $866.0 million in Q1 2025.